Bruker Corporation (NASDAQ:BRKR) – Stock analysts at Jefferies Group boosted their FY2017 earnings per share estimates for Bruker Corporation in a research report issued to clients and investors on Friday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will earn $1.12 per share for the year, up from their previous estimate of $1.11. Jefferies Group also issued estimates for Bruker Corporation’s Q1 2018 earnings at $0.30 EPS and Q4 2018 earnings at $0.37 EPS.

A number of other brokerages also recently issued reports on BRKR. BidaskClub upgraded Bruker Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Wells Fargo & Company cut Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $24.00 target price on shares of Bruker Corporation in a research note on Tuesday, September 26th. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, July 6th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 target price (up previously from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $26.70.

ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Forecast for Bruker Corporation (BRKR) Issued By Jefferies Group” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/23/fy2017-earnings-forecast-for-bruker-corporation-brkr-issued-by-jefferies-group.html.

Shares of Bruker Corporation (NASDAQ BRKR) opened at 30.54 on Monday. The stock has a 50 day moving average price of $29.93 and a 200-day moving average price of $27.63. Bruker Corporation has a 12 month low of $19.58 and a 12 month high of $31.12. The company has a market capitalization of $4.85 billion, a price-to-earnings ratio of 30.45 and a beta of 1.09.

Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.03. The firm had revenue of $414.90 million for the quarter, compared to analyst estimates of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS.

In related news, VP Mark Munch sold 21,061 shares of the stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Frank H. Laukien acquired 2,335 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the purchase, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at $1,035,106,062.54. The disclosure for this purchase can be found here. 35.20% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in BRKR. Acrospire Investment Management LLC grew its stake in Bruker Corporation by 496.1% in the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after purchasing an additional 3,185 shares in the last quarter. SG Americas Securities LLC bought a new position in Bruker Corporation in the second quarter worth approximately $111,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Bruker Corporation by 11.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after purchasing an additional 467 shares in the last quarter. Smithfield Trust Co. bought a new position in Bruker Corporation in the second quarter worth approximately $138,000. Finally, The Manufacturers Life Insurance Company grew its stake in Bruker Corporation by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after purchasing an additional 331 shares in the last quarter. 65.42% of the stock is currently owned by institutional investors.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.